Akiko Kiriyama

585 total citations
41 papers, 454 citations indexed

About

Akiko Kiriyama is a scholar working on Molecular Biology, Infectious Diseases and Virology. According to data from OpenAlex, Akiko Kiriyama has authored 41 papers receiving a total of 454 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 9 papers in Infectious Diseases and 8 papers in Virology. Recurrent topics in Akiko Kiriyama's work include HIV/AIDS drug development and treatment (9 papers), HIV Research and Treatment (8 papers) and Advanced Drug Delivery Systems (6 papers). Akiko Kiriyama is often cited by papers focused on HIV/AIDS drug development and treatment (9 papers), HIV Research and Treatment (8 papers) and Advanced Drug Delivery Systems (6 papers). Akiko Kiriyama collaborates with scholars based in Japan and France. Akiko Kiriyama's co-authors include Katsumi Iga, Kanji Takada, Nobuhito Shibata, Shigeru Negi, Shunsuke Kimura, Hiroaki Kitagishi, Koji Kano, Daisuke Inoue, Akiko Tanaka and Akira Yamamoto and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Angewandte Chemie International Edition and Biochemical and Biophysical Research Communications.

In The Last Decade

Akiko Kiriyama

39 papers receiving 450 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Akiko Kiriyama Japan 13 158 90 54 48 47 41 454
Kerry Estes United States 21 223 1.4× 139 1.5× 55 1.0× 10 0.2× 92 2.0× 41 1.0k
Herman Borghys Belgium 12 125 0.8× 86 1.0× 49 0.9× 8 0.2× 25 0.5× 25 537
Abeer M. Al-Ghananeem United States 15 197 1.2× 303 3.4× 58 1.1× 13 0.3× 63 1.3× 35 739
Inez C. J. van der Sandt Netherlands 9 138 0.9× 46 0.5× 6 0.1× 17 0.4× 235 5.0× 9 756
François Chouinard Canada 14 142 0.9× 95 1.1× 38 0.7× 32 0.7× 9 0.2× 16 659
Wesley R. Anderson United States 16 153 1.0× 107 1.2× 44 0.8× 5 0.1× 75 1.6× 38 535
Kakali De India 14 325 2.1× 40 0.4× 83 1.5× 20 0.4× 23 0.5× 32 898
Eun Ji Park South Korea 14 255 1.6× 35 0.4× 41 0.8× 16 0.3× 18 0.4× 34 755
Hossein Amini Iran 15 160 1.0× 55 0.6× 13 0.2× 6 0.1× 70 1.5× 41 603
Tae‐Sung Koo South Korea 17 235 1.5× 99 1.1× 65 1.2× 24 0.5× 40 0.9× 60 702

Countries citing papers authored by Akiko Kiriyama

Since Specialization
Citations

This map shows the geographic impact of Akiko Kiriyama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akiko Kiriyama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akiko Kiriyama more than expected).

Fields of papers citing papers by Akiko Kiriyama

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akiko Kiriyama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akiko Kiriyama. The network helps show where Akiko Kiriyama may publish in the future.

Co-authorship network of co-authors of Akiko Kiriyama

This figure shows the co-authorship network connecting the top 25 collaborators of Akiko Kiriyama. A scholar is included among the top collaborators of Akiko Kiriyama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akiko Kiriyama. Akiko Kiriyama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kimura, Shunsuke, et al.. (2024). Pharmacokinetic–Pharmacodynamic Analysis of pH-Responsive Doxorubicin-Releasing Micelles with Anticancer Activity. Molecular Pharmaceutics. 21(7). 3173–3185.
2.
Tanaka, Yuka, et al.. (2024). Variations in the inner core affect the pharmacokinetics of indomethacin-encapsulated polymeric micelles. International Journal of Pharmaceutics. 654. 123933–123933. 1 indexed citations
3.
Kiriyama, Akiko, Shigeru Negi, Hideki Yoshioka, et al.. (2023). A synthetic porphyrin as an effective dual antidote against carbon monoxide and cyanide poisoning. Proceedings of the National Academy of Sciences. 120(9). e2209924120–e2209924120. 11 indexed citations
4.
Kiriyama, Akiko, et al.. (2022). Pharmacokinetic/Pharmacodynamic Models of an Alzheimer’s Drug, Donepezil, in Rats. Drug Metabolism and Disposition. 51(3). 329–337. 3 indexed citations
5.
Kawashita, Eri, et al.. (2020). α2-Antiplasmin as a potential regulator of the spatial memory process and age-related cognitive decline. Molecular Brain. 13(1). 140–140. 2 indexed citations
6.
Inoue, Daisuke, Akiko Tanaka, Shunsuke Kimura, et al.. (2018). The relationship between in vivo nasal drug clearance and in vitro nasal mucociliary clearance: Application to the prediction of nasal drug absorption. European Journal of Pharmaceutical Sciences. 117. 21–26. 25 indexed citations
7.
Tanaka, Akiko, Tomoyuki Furubayashi, Mari Arai, et al.. (2018). Delivery of Oxytocin to the Brain for the Treatment of Autism Spectrum Disorder by Nasal Application. Molecular Pharmaceutics. 15(3). 1105–1111. 72 indexed citations
8.
Naruhashi, Kazumasa, et al.. (2016). Preparation and pharmaceutical evaluation of acetaminophen nano-fiber tablets: Application of a solvent-based electrospinning method for tableting. Biomedicine & Pharmacotherapy. 78. 14–22. 19 indexed citations
9.
10.
Watanabe, Kenji, Shigeru Negi, Yukio Sugiura, et al.. (2010). Binding of Multivalent Anionic Porphyrins to V3 Loop Fragments of an HIV‐1 Envelope and Their Antiviral Activity. Chemistry - An Asian Journal. 5(4). 825–834. 12 indexed citations
11.
Nishimura, Asako, et al.. (2009). Pharmacokinetic Profiles of Coenzyme Q<sub>10</sub>: Absorption of Three Different Oral Formulations in Rats. JOURNAL OF HEALTH SCIENCE. 55(4). 540–548. 12 indexed citations
12.
Kiriyama, Akiko, et al.. (2007). Analysis of hepatic metabolism affecting pharmacokinetics of propranolol in humans. International Journal of Pharmaceutics. 349(1-2). 53–60. 12 indexed citations
13.
Iga, Katsumi, et al.. (2006). A multi-sinusoidal compartment model as an alternative to the dispersion model for hepatic extraction kinetic analysis. 57(57). 105–113.
14.
Kiriyama, Akiko, et al.. (1999). Physiologically based pharmacokinetics of KNI-272, a tripeptide HIV-1 protease inhibitor. Biopharmaceutics & Drug Disposition. 20(4). 199–205. 3 indexed citations
15.
Kiriyama, Akiko, et al.. (1996). BINDING CHARACTERISTICS OF KNI-272 TO PLASMA PROTEINS, A NEW POTENT TRIPEPTIDE HIV PROTEASE INHIBITOR. Biopharmaceutics & Drug Disposition. 17(9). 739–751. 8 indexed citations
16.
Kiriyama, Akiko, et al.. (1996). THE BIOAVAILABILITY OF ORAL DOSAGE FORMS OF A NEW HIV-1 PROTEASE INHIBITOR, KNI-272, IN BEAGLE DOGS. Biopharmaceutics & Drug Disposition. 17(2). 125–134. 9 indexed citations
17.
Kiriyama, Akiko, et al.. (1995). Absorption of new HIV‐1 protease inhibitor, KNI‐272, after intraduodenal and intragastric administrations to rats: Effect of solvent. Biopharmaceutics & Drug Disposition. 16(4). 269–277. 4 indexed citations
18.
Kiriyama, Akiko, Kazuhiro Fujita, Shigeo Takemura, et al.. (1994). Plasma pharmacokinetics and urinary and biliary excretion of a new potent tripeptide HIV‐1 protease inhibitor, KNI‐272, in rats after intravenous administration. Biopharmaceutics & Drug Disposition. 15(7). 617–626. 7 indexed citations
19.
Kiriyama, Akiko, et al.. (1993). Distribution characteristics of immunosuppressants FK506 and cyclosporin A in the blood compartment. Biopharmaceutics & Drug Disposition. 14(8). 659–671. 19 indexed citations
20.
Kiriyama, Akiko, et al.. (1992). Effect of organic acids, trypsin inhibitors and dietary protein on the pharmacological activity of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats. International Journal of Pharmaceutics. 81(2-3). 133–141. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kerry Estes Breakdown of academic impact, for papers by Herman Borghys Breakdown of academic impact, for papers by Abeer M. Al-Ghananeem Breakdown of academic impact, for papers by Inez C. J. van der Sandt Breakdown of academic impact, for papers by François Chouinard Breakdown of academic impact, for papers by Wesley R. Anderson Breakdown of academic impact, for papers by Kakali De Breakdown of academic impact, for papers by Eun Ji Park Breakdown of academic impact, for papers by Hossein Amini Breakdown of academic impact, for papers by Tae‐Sung Koo
Rankless by CCL
2026